<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">22279543</PMID><DateCompleted><Year>2012</Year><Month>07</Month><Day>09</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1932-6203</ISSN><JournalIssue CitedMedium="Internet"><Volume>7</Volume><Issue>1</Issue><PubDate><Year>2012</Year></PubDate></JournalIssue><Title>PloS one</Title><ISOAbbreviation>PLoS One</ISOAbbreviation></Journal><ArticleTitle>Characterization of an isotype-dependent monoclonal antibody against linear neutralizing epitope effective for prophylaxis of enterovirus 71 infection.</ArticleTitle><Pagination><StartPage>e29751</StartPage><MedlinePgn>e29751</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e29751</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0029751</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Enterovirus 71 (EV71) is the main causative agent of Hand, Foot and Mouth disease (HFMD) and is associated with severe neurologic complications and mortalities. At present, there is no vaccine or therapeutic available for treatment.</AbstractText><AbstractText Label="METHODOLOGY/PRINCIPAL FINDING" NlmCategory="RESULTS">In this study, we generated two mAbs, denoted as mAb 51 and 53, both targeting the same linear epitope on VP1 capsid protein, spanning amino acids 215-219. In comparison, mAb 51 belonging to isotype IgM possesses neutralizing activity in vitro, whereas, mAb 53 belonging to isotype IgG1 does not have any neutralizing ability, even towards its homologous strain. When mAb 51 at 10 &#xb5;g/g of body weight was administered to the 2-week-old AG129 mice one day prior to lethal challenge, 100% in vivo passive protection was observed. In contrast, the isotype control group mice, injected with an irrelevant IgM antibody before the challenge, developed limb paralysis as early as day 6 post-infection. Histological examination demonstrated that mAb 51 was able to protect against pathologic changes such as neuropil vacuolation and neuronal loss in the spinal cord, which were typical in unprotected EV-71 infected mice. BLAST analyses of that epitope revealed that it was highly conserved among all EV71 strains, but not coxsachievirus 16 (CA16).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">We have defined a linear epitope within the VP1 protein and demonstrated its neutralizing ability to be isotype dependent. The neutralizing property and highly conserved sequence potentiated the application of mAb 51 and 53 for protection against EV71 infection and diagnosis respectively.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lim</LastName><ForeName>Xiao Fang</ForeName><Initials>XF</Initials><AffiliationInfo><Affiliation>Animal Health Biotechnology, Temasek Life Sciences Laboratory, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jia</LastName><ForeName>Qiang</ForeName><Initials>Q</Initials></Author><Author ValidYN="Y"><LastName>Khong</LastName><ForeName>Wei Xin</ForeName><Initials>WX</Initials></Author><Author ValidYN="Y"><LastName>Yan</LastName><ForeName>Benedict</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Premanand</LastName><ForeName>Balraj</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Alonso</LastName><ForeName>Sylvie</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Chow</LastName><ForeName>Vincent T K</ForeName><Initials>VT</Initials></Author><Author ValidYN="Y"><LastName>Kwang</LastName><ForeName>Jimmy</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>01</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS One</MedlineTA><NlmUniqueID>101285081</NlmUniqueID><ISSNLinking>1932-6203</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D036022">Capsid Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000939">Epitopes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007132">Immunoglobulin Isotypes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012367">RNA, Viral</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000911" MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000918" MajorTopicYN="N">Antibody Specificity</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015153" MajorTopicYN="N">Blotting, Western</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D036022" MajorTopicYN="N">Capsid Proteins</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002522" MajorTopicYN="N">Chlorocebus aethiops</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="N">Enterovirus A, Human</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004769" MajorTopicYN="N">Enterovirus Infections</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018604" MajorTopicYN="N">Epitope Mapping</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000939" MajorTopicYN="N">Epitopes</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007114" MajorTopicYN="N">Immunization</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007132" MajorTopicYN="N">Immunoglobulin Isotypes</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009500" MajorTopicYN="N">Neutralization Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012367" MajorTopicYN="N">RNA, Viral</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020133" MajorTopicYN="N">Reverse Transcriptase Polymerase Chain Reaction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017386" MajorTopicYN="N">Sequence Homology, Amino Acid</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014709" MajorTopicYN="N">Vero Cells</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Competing Interests: </b>The authors have declared that no competing interests exist.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2011</Year><Month>8</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2011</Year><Month>12</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>1</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>1</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>7</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2012</Year><Month>1</Month><Day>18</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22279543</ArticleId><ArticleId IdType="pmc">PMC3261156</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0029751</ArticleId><ArticleId IdType="pii">PONE-D-11-16816</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Schmidt NJ, Lennette EH, Ho HH. An apparently new enterovirus isolated from patients with disease of the central nervous system. J Infect Dis. 1974;129:304&#x2013;309.</Citation><ArticleIdList><ArticleId IdType="pubmed">4361245</ArticleId></ArticleIdList></Reference><Reference><Citation>Hagiwara A, Tagaya I, Yoneyama T. Epidemic of hand, foot and mouth disease associated with enterovirus 71 infection. Intervirology. 1978;9:60&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pubmed">202573</ArticleId></ArticleIdList></Reference><Reference><Citation>Blomberg J, Lycke E, Ahlfors K, Johnsson T, Wolontis S, et al. Letter: New enterovirus type associated with epidemic of aseptic meningitis and-or hand, foot, and mouth disease. Lancet. 1974;2:112.</Citation><ArticleIdList><ArticleId IdType="pubmed">4136956</ArticleId></ArticleIdList></Reference><Reference><Citation>Kennett ML, Birch CJ, Lewis FA, Yung AP, Locarnini SA, et al. Enterovirus type 71 infection in Melbourne. Bull World Health Organ. 1974;51:609&#x2013;615.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2366271</ArticleId><ArticleId IdType="pubmed">4377551</ArticleId></ArticleIdList></Reference><Reference><Citation>Chumakov M, Voroshilova M, Shindarov L, Lavrova I, Gracheva L, et al. Enterovirus 71 isolated from cases of epidemic poliomyelitis-like disease in Bulgaria. Arch Virol. 1979;60:329&#x2013;340.</Citation><ArticleIdList><ArticleId IdType="pubmed">228639</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagy G, Takatsy S, Kukan E, Mihaly I, Domok I. Virological diagnosis of enterovirus type 71 infections: experiences gained during an epidemic of acute CNS diseases in Hungary in 1978. Arch Virol. 1982;71:217&#x2013;227.</Citation><ArticleIdList><ArticleId IdType="pubmed">6285858</ArticleId></ArticleIdList></Reference><Reference><Citation>Samuda GM, Chang WK, Yeung CY, Tang PS. Monoplegia caused by Enterovirus 71: an outbreak in Hong Kong. Pediatr Infect Dis J. 1987;6:206&#x2013;208.</Citation><ArticleIdList><ArticleId IdType="pubmed">3562141</ArticleId></ArticleIdList></Reference><Reference><Citation>Bible JM, Iturriza-Gomara M, Megson B, Brown D, Pantelidis P, et al. Molecular epidemiology of human enterovirus 71 in the United Kingdom from 1998 to 2006. J Clin Microbiol. 2008;46:3192&#x2013;3200.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2566106</ArticleId><ArticleId IdType="pubmed">18650362</ArticleId></ArticleIdList></Reference><Reference><Citation>Lum LC, Wong KT, Lam SK, Chua KB, Goh AY, et al. Fatal enterovirus 71 encephalomyelitis. J Pediatr. 1998;133:795&#x2013;798.</Citation><ArticleIdList><ArticleId IdType="pubmed">9842048</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu CC, Tseng HW, Wang SM, Wang JR, Su IJ. An outbreak of enterovirus 71 infection in Taiwan, 1998: epidemiologic and clinical manifestations. J Clin Virol. 2000;17:23&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">10814935</ArticleId></ArticleIdList></Reference><Reference><Citation>Bendig JW, Fleming DM. Epidemiological, virological, and clinical features of an epidemic of hand, foot, and mouth disease in England and Wales. Commun Dis Rep CDR Rev. 1996;6:R81&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pubmed">8664928</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang L-Y. Enterovirus 71 in Taiwan. Pediatrics &amp; Neonatology. 2008;49:103&#x2013;112.</Citation><ArticleIdList><ArticleId IdType="pubmed">19054914</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang LC, Tang SQ, Li YM, Zhao HL, Dong CH, et al. A comparison of the biological characteristics of EV71 C4 subtypes from different epidemic strains. Virol Sin. 2010;25:98&#x2013;106.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8227828</ArticleId><ArticleId IdType="pubmed">20960306</ArticleId></ArticleIdList></Reference><Reference><Citation>Hogle JM, Chow M, Filman DJ. Three-dimensional structure of poliovirus at 2.9 A resolution. Science. 1985;229:1358&#x2013;1365.</Citation><ArticleIdList><ArticleId IdType="pubmed">2994218</ArticleId></ArticleIdList></Reference><Reference><Citation>Li C, Wang H, Shih SR, Chen TC, Li ML. The efficacy of viral capsid inhibitors in human enterovirus infection and associated diseases. Curr Med Chem. 2007;14:847&#x2013;856.</Citation><ArticleIdList><ArticleId IdType="pubmed">17430140</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan CS, Cardosa MJ. High-titred neutralizing antibodies to human enterovirus 71 preferentially bind to the N-terminal portion of the capsid protein VP1. Arch Virol. 2007;152:1069&#x2013;1073.</Citation><ArticleIdList><ArticleId IdType="pubmed">17318736</ArticleId></ArticleIdList></Reference><Reference><Citation>Foo DG, Alonso S, Phoon MC, Ramachandran NP, Chow VT, et al. Identification of neutralizing linear epitopes from the VP1 capsid protein of Enterovirus 71 using synthetic peptides. Virus Res. 2007;125:61&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pubmed">17222936</ArticleId></ArticleIdList></Reference><Reference><Citation>Tee KK, Lam TT, Chan YF, Bible JM, Kamarulzaman A, et al. Evolutionary genetics of human enterovirus 71: origin, population dynamics, natural selection, and seasonal periodicity of the VP1 gene. J Virol. 2010;84:3339&#x2013;3350.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2838098</ArticleId><ArticleId IdType="pubmed">20089660</ArticleId></ArticleIdList></Reference><Reference><Citation>Dwyer JM. Manipulating the immune system with immune globulin. N Engl J Med. 1992;326:107&#x2013;116.</Citation><ArticleIdList><ArticleId IdType="pubmed">1727218</ArticleId></ArticleIdList></Reference><Reference><Citation>Kimura-Kuroda J, Yasui K. Protection of mice against Japanese encephalitis virus by passive administration with monoclonal antibodies. J Immunol. 1988;141:3606&#x2013;3610.</Citation><ArticleIdList><ArticleId IdType="pubmed">2460542</ArticleId></ArticleIdList></Reference><Reference><Citation>Geller TJ, Condie D. A case of protracted coxsackie virus meningoencephalitis in a marginally immunodeficient child treated successfully with intravenous immunoglobulin. J Neurol Sci. 1995;129:131&#x2013;133.</Citation><ArticleIdList><ArticleId IdType="pubmed">7608726</ArticleId></ArticleIdList></Reference><Reference><Citation>Abzug MJ, Keyserling HL, Lee ML, Levin MJ, Rotbart HA. Neonatal enterovirus infection: virology, serology, and effects of intravenous immune globulin. Clin Infect Dis. 1995;20:1201&#x2013;1206.</Citation><ArticleIdList><ArticleId IdType="pubmed">7620000</ArticleId></ArticleIdList></Reference><Reference><Citation>McKinney RE, Jr, Katz SL, Wilfert CM. Chronic enteroviral meningoencephalitis in agammaglobulinemic patients. Rev Infect Dis. 1987;9:334&#x2013;356.</Citation><ArticleIdList><ArticleId IdType="pubmed">3296100</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang SM, Liu CC. Enterovirus 71: epidemiology, pathogenesis and management. Expert Rev Anti Infect Ther. 2009;7:735&#x2013;742.</Citation><ArticleIdList><ArticleId IdType="pubmed">19681701</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X, Mao C, Ma S, Wang X, Sun Z, et al. Generation of neutralizing monoclonal antibodies against Enterovirus 71 using synthetic peptides. Biochem Biophys Res Commun. 2009;390:1126&#x2013;1128.</Citation><ArticleIdList><ArticleId IdType="pubmed">19799860</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu CC, Chou AH, Lien SP, Lin HY, Liu SJ, et al. Identification and characterization of a cross-neutralization epitope of Enterovirus 71. Vaccine. 2011;29:4362&#x2013;4372.</Citation><ArticleIdList><ArticleId IdType="pubmed">21501643</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang GH, Luo YJ, Wu XY, Si BY, Lin L, et al. Monoclonal antibody induced with inactived EV71-Hn2 virus protects mice against lethal EV71-Hn2 virus infection. Virology Journal. 2010;7:106.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2887433</ArticleId><ArticleId IdType="pubmed">20500892</ArticleId></ArticleIdList></Reference><Reference><Citation>Feinstein A, Munn EA, Richardson NE. The three-dimensional conformation of M and A globulin molecules. Ann N Y Acad Sci. 1971;190:104&#x2013;121.</Citation><ArticleIdList><ArticleId IdType="pubmed">5290007</ArticleId></ArticleIdList></Reference><Reference><Citation>Armstrong SJ, Outlaw MC, Dimmock NJ. Morphological studies of the neutralization of influenza virus by IgM. J Gen Virol. 1990;71(Pt 10):2313&#x2013;2319.</Citation><ArticleIdList><ArticleId IdType="pubmed">2230737</ArticleId></ArticleIdList></Reference><Reference><Citation>Dimmock NJ. Mechanisms of neutralization of animal viruses. J Gen Virol. 1984;65(Pt 6):1015&#x2013;1022.</Citation><ArticleIdList><ArticleId IdType="pubmed">6202836</ArticleId></ArticleIdList></Reference><Reference><Citation>Diamond MS, Shrestha B, Marri A, Mahan D, Engle M. B cells and antibody play critical roles in the immediate defense of disseminated infection by West Nile encephalitis virus. J Virol. 2003;77:2578&#x2013;2586.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC141119</ArticleId><ArticleId IdType="pubmed">12551996</ArticleId></ArticleIdList></Reference><Reference><Citation>Salinas-Carmona MC, Perez-Rivera I. Humoral immunity through immunoglobulin M protects mice from an experimental actinomycetoma infection by Nocardia brasiliensis. Infect Immun. 2004;72:5597&#x2013;5604.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC517546</ArticleId><ArticleId IdType="pubmed">15385456</ArticleId></ArticleIdList></Reference><Reference><Citation>Roehrig JT, Nash D, Maldin B, Labowitz A, Martin DA, et al. Persistence of virus-reactive serum immunoglobulin m antibody in confirmed west nile virus encephalitis cases. Emerg Infect Dis. 2003;9:376&#x2013;379.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2958550</ArticleId><ArticleId IdType="pubmed">12643836</ArticleId></ArticleIdList></Reference><Reference><Citation>Foo DG, Alonso S, Chow VT, Poh CL. Passive protection against lethal enterovirus 71 infection in newborn mice by neutralizing antibodies elicited by a synthetic peptide. Microbes Infect. 2007;9:1299&#x2013;1306.</Citation><ArticleIdList><ArticleId IdType="pubmed">17890123</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu F, Yan Q, Wang H, Niu J, Li L, et al. Performance of detecting IgM antibodies against enterovirus 71 for early diagnosis. PLoS One. 2010;5:e11388.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2894942</ArticleId><ArticleId IdType="pubmed">20613983</ArticleId></ArticleIdList></Reference><Reference><Citation>Sigounas G, Harindranath N, Donadel G, Notkins AL. Half-life of polyreactive antibodies. J Clin Immunol. 1994;14:134&#x2013;140.</Citation><ArticleIdList><ArticleId IdType="pubmed">8195315</ArticleId></ArticleIdList></Reference><Reference><Citation>Meng T, Kolpe AB, Kiener TK, Chow VT, Kwang J. Display of VP1 on the Surface of Baculovirus and Its Immunogenicity against Heterologous Human Enterovirus 71 Strains in Mice. PLoS One. 2011;6:e21757.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3128602</ArticleId><ArticleId IdType="pubmed">21747954</ArticleId></ArticleIdList></Reference><Reference><Citation>Reed LJ, Muench H. A simple method of estimating fifty percent endpoints. The American Journal of Hygiene. 1938;27:493&#x2013;497.</Citation></Reference><Reference><Citation>Aarthi D, Ananda Rao K, Robinson R, Srinivasan VA. Validation of binary ethyleneimine (BEI) used as an inactivant for foot and mouth disease tissue culture vaccine. Biologicals. 2004;32:153&#x2013;156.</Citation><ArticleIdList><ArticleId IdType="pubmed">15536046</ArticleId></ArticleIdList></Reference><Reference><Citation>Bahnemann HG. Binary ethylenimine as an inactivant for foot-and-mouth disease virus and its application for vaccine production. Arch Virol. 1975;47:47&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pubmed">167679</ArticleId></ArticleIdList></Reference><Reference><Citation>Yokoyama WM, Christensen M, Santos GD, Miller D. Production of monoclonal antibodies. Curr Protoc Immunol. 2006;Chapter 2:Unit 2 5.</Citation><ArticleIdList><ArticleId IdType="pubmed">18432969</ArticleId></ArticleIdList></Reference><Reference><Citation>Yokoyama WM. Monoclonal antibody supernatant and ascites fluid production. Curr Protoc Immunol. 2001;Chapter 2:Unit 2 6.</Citation><ArticleIdList><ArticleId IdType="pubmed">18432770</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>